Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Regulatory News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TR-1: Notification of major holdings

8 Nov 2023 13:58

RNS Number : 8260S
Redx Pharma plc
08 November 2023
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Redx Pharma PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii: increase in total voting rights of issuer

X

3. Details of person subject to the notification obligationiv

Name

Redmile Group, LLC

City and country of registered office (if applicable)

San Francisco, USA

4. Full name of shareholder(s) (if different from 3.)v

Name

RM Special Holdings 3, LLC

RedCo II Master Fund, L.P.

City and country of registered office (if applicable)

San Francisco, USA

5. Date on which the threshold was crossed or reachedvi:

07/11/2023

6. Date on which issuer notified (DD/MM/YYYY):

08/11/2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

71.18

N/A

71.18

276,890,319

Position of previous notification (if

applicable)

73.60

N/A

73.60

245,341,627

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares

GB00BSNB6S51

N/A

276,890,319

N/A

276,890,319

SUBTOTAL 8. A

276,890,319

71.18

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Redmile Group, LLC

RM Special Holdings 3, LLC

56.01

N/A

56.01

Redmile Group, LLC

RedCo II Master Fund, L.P.

15.17

N/A

15.17

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

Redmile Group, LLC manages the investments of RM Special Holdings 3, LLC and RedCo II Master Fund, L.P.

 

Place of completion

San Francisco, USA

Date of completion

07/11/2023

 

 

Notes

 

i Please note that national forms may vary due to specific national legislation (Article 3(1a) of Directive 2004/109/EC) as for instance the applicable thresholds or information regarding capital holdings.

 

ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g. address, LEI, domestic number identity). Indicate in the relevant section whether the issuer is a non UK issuer.

 

iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g. expiring of financial instruments) or acting in concert.

 

iv This should be the full name of (a) the shareholder; (b) the natural person or legal entity acquiring, disposing of or exercising voting rights in the cases provided for in DTR5.2.1 (b) to (h)/ Article 10 (b) to (h) of Directive 2004/109/EC; (c) all parties to the agreement referred to in Article 10 (a) of Directive 2004/109/EC (DTR5.2.1 (a)) or (d) the holder of financial instruments referred to in Article 13(1) of Directive 2004/109/EC (DTR5.3.1).

 

As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g. same or different total positions of the parties, entering or exiting of acting in concert by a single party) the standard form does not provide for a specific method how to notify cases of acting in concert.

 

In relation to the transactions referred to in points (b) to (h) of Article 10 of Directive 2004/109/EC (DTR5.2.1 (b) to (h)), the following list is provided as indication of the persons who should be mentioned:

 

- in the circumstances foreseen in letter (b) of Article 10 of that Directive (DTR5.2.1 (b)), the natural person or legal entity that acquires the voting rights and is entitled to exercise them under the agreement and the natural person or legal entity who is transferring temporarily for consideration the voting rights;

 

- in the circumstances foreseen in letter (c) of Article 10 of that Directive (DTR5.2.1 (c)), the natural person or legal entity holding the collateral, provided the person or entity controls the voting rights and declares its intention of exercising them, and natural person or legal entity lodging the collateral under these conditions;

 

- in the circumstances foreseen in letter (d) of Article 10 of that Directive (DTR5.2.1 (d)), the natural person or legal entity who has a life interest in shares if that person or entity is entitled to exercise the voting rights attached to the shares and the natural person or legal entity who is disposing of the voting rights when the life interest is created;

 

- in the circumstances foreseen in letter (e) of Article 10 of that Directive (DTR5.2.1 (e)), the controlling natural person or legal entity and, provided it has a notification duty at an individual level under Article 9 (DTR 5.1), under letters (a) to (d) of Article 10 of that Directive (DTR5.2.1 (a) to (d)) or under a combination of any of those situations, the controlled undertaking;

 

- in the circumstances foreseen in letter (f) of Article 10 of that Directive (DTR5.2.1 (f)), the deposit taker of the shares, if he can exercise the voting rights attached to the shares deposited with him at his discretion, and the depositor of the shares allowing the deposit taker to exercise the voting rights at his discretion;

 

- in the circumstances foreseen in letter (g) of Article 10 of that Directive (DTR5.2.1 (g)), the natural person or legal entity that controls the voting rights;

 

- in the circumstances foreseen in letter (h) of Article 10 of that Directive (DTR5.2.1 (h)), the proxy holder, if he can exercise the voting rights at his discretion, and the shareholder who has given his proxy to the proxy holder allowing the latter to exercise the voting rights at his discretion (e.g. management companies).

 

v Applicable in the cases provided for in Article 10 (b) to (h) of Directive 2004/109/EC (DTR5.2.1 (b) to (h). This should be the full name of the shareholder who is the counterparty to the natural person or legal entity referred to in Article 10 of that Directive (DTR5.2) unless the percentage of voting rights held by the shareholder is lower than the lowest notifiable threshold for the disclosure of voting rights holdings in accordance with national practices (e.g. identification of funds managed by management companies).

 

vi The date on which threshold is crossed or reached should be the date on which the acquisition or disposal took place or the other reason triggered the notification obligation. For passive crossings, the date when the corporate event took effect.

 

vii The total number of voting rights shall be composed of all the shares, including depository receipts representing shares, to which voting rights are attached even if the exercise thereof is suspended.

 

viii If the holding has fallen below the lowest applicable threshold in accordance with national law, please note that it might not be necessary in accordance with national law to disclose the extent of the holding, only that the new holding is below that threshold.

 

ix In case of combined holdings of shares with voting rights attached "direct holding" and voting rights "indirect holding", please split the voting rights number and percentage into the direct and indirect columns - if there is no combined holdings, please leave the relevant box blank.

 

x Date of maturity/expiration of the financial instrument i.e. the date when right to acquire shares ends.

 

xi If the financial instrument has such a period - please specify this period - for example once every 3 months starting from [date].

 

xii In case of cash settled instruments the number and percentages of voting rights is to be presented on a delta-adjusted basis (Article 13(1a) of Directive 2004/109/EC) (DTR 5.3.3.A).

 

xiii If the person subject to the notification obligation is either controlled and/or does control another undertaking then the second option applies.

 

xiv The full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity has to be presented also in the cases, in which only on subsidiary level a threshold is crossed or reached and the subsidiary undertaking discloses the notification as only thus the markets get always the full picture of the group holdings. In case of multiple chains through which the voting rights and/or financial instruments are effectively held the chains have to be presented chain by chain leaving a row free between different chains (e.g.: A, B, C, free row, A, B, D, free row, A, E, F etc.).

 

xv The names of controlled undertakings through which the voting rights and/or financial instruments are effectively held have to be presented irrespectively whether the controlled undertakings cross or reach the lowest applicable threshold themselves.

 

xvi Example: Correction of a previous notification.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUWVOROVUARAA
Date   Source Headline
1st Nov 20217:00 amRNSAppointment of Non-Executive Chair
11th Oct 20217:00 amRNSR&D Day and New Clinical Data for ROCK2 Inhibitor
5th Oct 20217:00 amRNSRedx to host Virtual R&D Day on 11 October 2021
27th Sep 20218:00 amRNSExercise of Options and Total Voting Rights
20th Sep 20214:59 pmRNSRedx Presents Encouraging Phase 1 Data for RXC004
17th Sep 202111:06 amRNSSecond Price Monitoring Extn
17th Sep 202111:00 amRNSPrice Monitoring Extension
16th Sep 202112:16 pmRNSPrice Monitoring Extension
16th Sep 202112:15 pmRNSSecond Price Monitoring Extn
16th Sep 202112:12 pmRNSSecond Price Monitoring Extn
16th Sep 202112:08 pmRNSPrice Monitoring Extension
14th Sep 20212:05 pmRNSSecond Price Monitoring Extn
14th Sep 20212:00 pmRNSPrice Monitoring Extension
14th Sep 202111:05 amRNSSecond Price Monitoring Extn
14th Sep 202111:00 amRNSPrice Monitoring Extension
13th Sep 20217:00 amRNSRXC004 Phase 1 data to be presented at ESMO 2021
2nd Sep 20217:00 amRNSMilestone Payment from Jazz Pharmaceuticals
27th Jul 20217:00 amRNSRedx Announces Phase 2 Dose Selection of RXC004
8th Jul 20211:43 pmRNSExercise of Options and Total Voting Rights
1st Jul 202111:08 amRNSNew Grant of Options and Director/PDMR Dealing
17th Jun 20217:00 amRNSRedx Receives Milestone Payment for RXC006
7th Jun 20217:00 amRNSInterim results for the six months ended 31 March
4th Jun 20217:00 amRNSChange of Auditor
3rd Jun 20217:00 amRNSFirst Subject Dosed in Phase 1 Study with RXC007
1st Jun 20217:00 amRNSDirectorate Change
24th May 20217:00 amRNSNotice of Interim Results
19th May 20217:00 amRNSAppointment of Non-Executive Director
5th May 20217:00 amRNSAppointment of Peter Collum as CFO
30th Apr 20219:00 amRNSConfirmation of post offer intention statements
28th Apr 20217:00 amRNSDosing of first patients with RXC004 and Anti-PD1
29th Mar 20219:00 amRNSRedx to present at AACR
15th Mar 20217:00 amRNSAppointment of Joint Broker
2nd Mar 202112:38 pmRNSResult of AGM and Directorate change
1st Mar 20219:57 amRNSNew Grant of Options
25th Feb 20217:00 amRNSPresentation at Cowen Healthcare Conference
5th Feb 20215:23 pmRNSNotice of AGM
27th Jan 20217:00 amRNSFinal Results for the Year Ended 30 September 2020
14th Jan 20217:00 amRNSNotice of Preliminary Results
29th Dec 20207:00 amRNSTR-1: Notification of major holdings
23rd Dec 20209:00 amRNSShare Purchases by Directors
22nd Dec 20205:13 pmRNSTR-1: Notification of major holdings
22nd Dec 20208:30 amRNSAdmission of Placing
21st Dec 202012:26 pmRNSResults of Open Offer and General Meeting
2nd Dec 20207:10 amRNSNew Grant of Options
2nd Dec 20207:00 amRNSPlacing and Open Offer Announcement
27th Oct 20207:00 amRNSAppointment of Chief Medical Officer
9th Sep 20207:00 amRNSResearch collaboration with Jazz Pharmaceuticals
3rd Sep 20203:00 pmRNSTR-1: Notification of major holdings
17th Aug 20202:05 pmRNSSecond Price Monitoring Extn
17th Aug 20202:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.